Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells by Ranganathan, Prathibha et al.
BioMed  Central
Page 1 of 18
(page number not for citation purposes)
BMC Genomics
Open Access Research article
Expression profiling of genes regulated by TGF-beta: Differential 
regulation in normal and tumour cells
Prathibha Ranganathan1, Animesh Agrawal1, Raghu Bhushan1, 
Aravinda K Chavalmane1, Ravi Kiran Reddy Kalathur1, Takashi Takahashi2 
and Paturu Kondaiah*1
Address: 1Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India and 2Division 
of Molecular Carcinogenesis, Centre for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Japan
Email: Prathibha Ranganathan - pratiba@mrdg.iisc.ernet.in; Animesh Agrawal - animesh.agrawal@gmail.com; 
Raghu Bhushan - raghubhushanin@yahoo.co.in; Aravinda K Chavalmane - aravi_ck@yahoo.com; Ravi Kiran Reddy Kalathur - ravi@titus.u-
strasbg.fr; Takashi Takahashi - tak@med.nagoya-u.ac.jp; Paturu Kondaiah* - paturu@mrdg.iisc.ernet.in
* Corresponding author    
Abstract
Background: TGF-beta is one of the key cytokines implicated in various disease processes
including cancer. TGF-beta inhibits growth and promotes apoptosis in normal epithelial cells and in
contrast, acts as a pro-tumour cytokine by promoting tumour angiogenesis, immune-escape and
metastasis. It is not clear if various actions of TGF-beta on normal and tumour cells are due to
differential gene regulations. Hence we studied the regulation of gene expression by TGF-beta in
normal and cancer cells.
Results: Using human 19 K cDNA microarrays, we show that 1757 genes are exclusively regulated
by TGF-beta in A549 cells in contrast to 733 genes exclusively regulated in HPL1D cells. In addition,
267 genes are commonly regulated in both the cell-lines. Semi-quantitative and real-time qRT-PCR
analysis of some genes agrees with the microarray data. In order to identify the signalling pathways
that influence TGF-beta mediated gene regulation, we used specific inhibitors of p38 MAP kinase,
ERK kinase, JNK kinase and integrin signalling pathways. The data suggest that regulation of majority
of the selected genes is dependent on at least one of these pathways and this dependence is cell-
type specific. Interestingly, an integrin pathway inhibitor, RGD peptide, significantly affected TGF-
beta regulation of Thrombospondin 1 in A549 cells.
Conclusion: These data suggest major differences with respect to TGF-beta mediated gene
regulation in normal and transformed cells and significant role of non-canonical TGF-beta pathways
in the regulation of many genes by TGF-beta.
Background
TGF-β is a multifunctional cytokine that plays important
patho-physiological roles in mammals. There are three
mammalian isoforms that are involved in several develop-
mental processes as has been shown by the knock-out
mice models [1]. TGF-β has a major role to play in the ini-
tiation and progression of cancer. This is supported by
several studies which have shown defects in various com-
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ponents of the TGF-β signalling pathway in many cancers
[2]. TGF-β has a dual role in carcinogenesis [3]. Initially it
acts as a tumour suppressor and causes growth arrest of
epithelial cells and cells in the early stages of cancer [4].
But in an established tumour, TGF-β exerts an effect which
is favourable for the survival, progression and metastasis
of the tumour [5,6] by promoting epithelial-mesenchy-
mal transition (EMT), angiogenesis and escape from
immune surveillance [7]. Studies using mouse models
have shown that an intact TGF-β signalling is essential for
the metastasis of breast cancer [8,9]. These observations
indicate that the normal epithelial cells show differential
response to TGF-β as compared to the tumour they give
rise to. Supporting this, it has been shown that prostate
tumour cells show invasion in response to TGF-β and not
non-tumourigenic cells [10]. Differential gene expression
mediated by TGF-β has been reported in tumour cells and
normal cells. For example, in response to TGF-β, tumour
cells show increase in the production of proteases and
down regulation of the inhibitors of proteases, whereas
this is not observed in the normal cells [11-14]. However,
there is no clear understanding of the mechanism (s)
responsible for differential responses of various cell types
to TGF-β. Since a role for TGF-β has been established in
several pathological conditions, this pathway is a very
attractive target for therapeutic intervention. This requires
identification of targets of TGF-β in different cell-types
and their mechanism of regulation, particularly in un-
transformed and transformed cells. In this study, we show
differential regulation of several genes by TGF-β in two
different cell-lines, HPL1D and A549 and also propose a
significant role for the MAP kinase pathway in TGF-β
mediated gene regulations.
Results
Gene expression profiling of HPL1D and A549 cells in 
response to TGF-β
To identify the TGF-β regulated genes in normal and
tumour cells, we chose HPL1D and A549 cells. HPL1D is
an immortalized lung epithelial cell-line that is growth
inhibited by TGF-β, similar to many epithelial cells [15].
A549 is a lung adenocarcinoma cell-line that has been
known to respond to TGF-β treatment [16]. The cells were
treated with human recombinant TGF-β 1 for 1, 4 and 12
hours and the RNAs extracted from these cells were used
for microarray experiments using human 19 k arrays.
Genes which were either up (> 1.3 fold) or down regu-
lated (< 0.33 fold) at any one of the time points have been
considered as regulated by TGF-β in the respective cell-
line. In HPL1D, 1000 genes were regulated by TGF-β treat-
ment and of these, 917 genes were up regulated and 83
genes were down regulated. In A549, 2024 genes were reg-
ulated by TGF-β and of these, 1714 genes were up regu-
lated and 310 genes were down regulated by TGF-β
treatment. The log2 transformed data of the genes regu-
lated by TGF-β in HPL1D and A549 cells are shown as
hierarchical cluster diagrams (Fig. 1a &1b). The expres-
sion profiling data of HPL1D and A549 in response to
TGF-β has been submitted to Gene Expression Omnibus
(accession number- GSE7436).
Comparison of gene expression profiles of HPL1D and 
A549 in response to TGF-β
When the gene expression profiles of HPL1D and A549
cell-lines in response to TGF-β 1 were compared, it was
found that 267 genes were regulated in both the cell-lines
in a similar manner but with different kinetics. The list of
genes regulated commonly in both HPL1D and A549 is
shown in additional file 1 (Table S1). A hierarchical clus-
ter diagram is shown in figure 2a and a Venn diagram
depicting the number of genes commonly and differen-
tially regulated in A549 and HPL1D are shown in figure
2b. 1757 genes are exclusively regulated by TGF-β in A549
cells, (see additional file 2 Table S2) and 733 genes are
exclusively regulated by TGF-β in HPL1D cells (see addi-
tional file 3, Table S3). Representative clusters of each of
the sub-classes of genes are shown in figure 2c.
Validation of microarray results by qRT-PCR
The microarray data have been validated by real time and
semi-quantitative RT-PCR. TMEPA, TGFBIP, IGFBP7,
Integrin α V, TSP-1, MMP2 and TGM2 were studied by real
time qRT-PCR as described in the methods. The primer
sequences used for qRT-PCR are shown in table 1. Any
gene is considered as regulated by TGF-β if qRT-PCR
results showed > two fold regulation as compared to
untreated cells. As shown in figure 3 and 4, TMEPA, TGF-
BIP and MMP2 are regulated by TGF-β 1 in both HPL1D
and A549 cell-lines. In HPL1D, induction of TGFBIP and
TMEPA by TGF-β is seen after 4 hours of treatment and
increases with prolonged incubation. The induction of
MMP2 by TGF-β is seen 6 hours onwards, whereas, there
is no regulation of the genes IGFBP7, TSP-1, TGM2 after
TGF-β treatment. Integrin αV, showed a 1.8 fold regula-
tion after 24 hours of treatment with TGF-β. In A549, the
induction of all these genes except TGM2 is observed after
4 hours of treatment and increase progressively with time,
whereas, the induction of TGM2 increases till 12 hours
and then declines. In addition, regulation of few other
genes by TGF-β such as fibronectin 1, ZF36, S100A2, Tβ
RI, ACTA2, T-plastin, keratin 7 and v-jun were assessed by
semi-quantitative RT-PCR (See additional file 4, Fig. S1A).
The data suggest that all these genes are regulated by 1.5 –
2.0 fold in HPL1D cells (See additional file 4, Fig. S1B).
However, in A549 cells, the regulation of ZF36, ACTA2,
Keratin 7, Tβ RI and v-jun is > 2.0 fold whereas, FN1, T-
plastin and S100A2 is 1.5–2.0 fold (See additional file 4,
Fig. S1C).BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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Functional categories of genes regulated by TGF-β in 
HPL1D and A549
The lists of the regulated genes were fed into DAVID data-
base (database for annotation, visualization and inte-
grated discovery [17]. Based on the functions of the genes
assigned by DAVID, genes were classified into the follow-
ing categories. In HPL1D, TGF-β regulated genes belong to
(a) regulation of actin cytoskeleton (table 2), (b) Focal
adhesion (table 3) and (c) Wnt signalling pathways (table
4). In A549, TGF-β modulated genes belong to (a) MAP
kinase signalling (table 5), (b) tight junction (table 6), (c)
adherans junction (table 7) (d) focal adhesion (table 8)
(e) insulin signalling (table 9) (f) regulation of actin
cytoskeleton (table 10) and (g) Wnt signalling (table 11).
Effect of inhibiting the MAPK pathways on the TGF-β 
mediated gene regulation
TGF-β modulates gene expression through phosphoryla-
tion of SMAD proteins. However, several studies show a
role for MAP kinase pathway in TGF-β mediated gene reg-
ulation both in a SMAD dependent and independent
manner [18-20]. Hence, inhibitors of MAP kinase path-
Hierarchical clustering of genes regulated by TGF-β in (a) HPL1D and (b) A549 cells Figure 1
Hierarchical clustering of genes regulated by TGF-β in (a) HPL1D and (b) A549 cells. The genes regulated by TGF-
β (described in materials and methods) were clustered using Avadis 3.3 Prophetic software. The data was clustered on rows by 
one way complete linkage – hierarchical clustering using Euclidean distance metric. Microarrays have been done in duplicate on 
RNAs isolated from cells after 1, 4 and 12 hours of treatment with TGF-β with paired controls at every time point. The den-
drogram on the left shows the different clusters into which the TGF-β regulated genes segregated. Red indicates genes induced 
by TGF-β treatment, green indicates genes repressed by TGF-β treatment and black suggests no regulation.
1hr 12hr 4hr 1hr 12hr 4hr
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way components, SB203580 (p38), PD98059 (ERK) and
JNK inhibitor 1-L form were used to assess the role of p38,
ERK and JNK pathways in the regulation of gene expres-
sion by TGF-β. In A549 cells, regulation of IGFBP7 by
TGF-β is independent of the p38, ERK and the JNK path-
ways. Induction of Integrin αV, MMP2, TMEPA and TGM2
by TGF-β is partially dependent on the ERK pathway; and
MMP2, TGFBIP, TGM2 and TSP-1 regulation by TGF-β is
partially dependent on the p38 pathway. The induction of
Integrin αV is partially affected by blocking the JNK path-
way (Fig. 5). In HPL1D cells, Intgerin αV, MMP2 and TGF-
BIP regulation by TGF-β is affected by blocking the p38
MAP kinase pathway, none of the gene regulations by
TGF-β seem to be affected by blocking the ERK pathway
and the induction of TMEPA by TGF-β is dependent on
the JNK pathway (Fig. 6).
Effect of blocking the Integrin-linked signalling pathway in 
A549 cells
Apart from the various signalling pathways and phenom-
ena modulated by TGF-β in both normal and tumour
cells, a pathway which is likely be differentially regulated
is the Integrin-αV linked signalling pathway. Integrin αV
is induced by TGF-β in A549 cells to about 3.5 fold as
compared to 1.8 fold in HPL1D. Integrin αV is known to
mediate some actions of TGF-β [21,22]. In order to test if
some of the genes regulated by TGF-β are due to activation
of Integrin αV, the activation of this pathway was blocked
Comparison of genes regulated by TGF-β in HPL1D and A549 cells Figure 2
Comparison of genes regulated by TGF-β in HPL1D and A549 cells. a, Hierarchical clustering of genes regulated by TGF-
β in HPL1D and A549 cells Genes regulated by TGF-β in HPL1D and A549 cells were clustered using Avadis 3.3 software. For 
this comparison only those genes for which expression values are available in both the cell-lines have been considered. The 
dendrogram on the left shows different clusters of genes segregated according to the pattern of regulation in the two cell-lines. 
b, Venn diagram showing the genes regulated by TGF-β either common or exclusively to the cell-lines and c, Expanded clusters showing 
sub-classes of genes regulated by TGF-β in HPL1D and A549 (derived from Figure 2a); A, Genes regulated by TGF-β in both 
HPL1D and A549 (267 genes); B, Genes regulated by TGF-β in A549 and not in HPL1D (1757 genes); C, Genes regulated by 
TGF-β in HPL1D and not in A549 (733 genes).
HPL1D A549 a
HPL1D A549
C
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c
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qRT-PCR analyses of selected genes (TMEPA, TGFBIP, IGFBP7, Integrin αV, TSP-1, MMP2, TGM2) with respect to TGF-β  treatment in A549 cells Figure 3
qRT-PCR analyses of selected genes (TMEPA, TGFBIP, IGFBP7, Integrin αV, TSP-1, MMP2, TGM2) with 
respect to TGF-β treatment in A549 cells. The cells were grown to 90% confluence, washed with serum free medium 
and treated with 5ng/ml TGF-β 1 for 1, 4, 6, 12 and 24 hours along with untreated controls at each time-point. Two microgram 
of total RNA from each treatment was reverse transcribed and cDNA equivalent to 10ng total RNA was used for the PCR 
reactions. The graphs represent the fold change over untreated controls after normalization with the expression of RPL35a. 
The bars show mean ± SD of two experiments of the PCR reactions done in duplicates.
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Table 1: List of genes selected for validation by real-time RT-PCR
Gene Name Fold regulation in microarray Primer sequences
HPL1D cells A549 cells
TGF-β induced protein 68 kDa (TGFBIP) 1.8 2.8 F 5' tgtgtgctgaagccatcgttg 3'
R 5' ccggcttgtctgaaaaggtca 3'
Trans membrane prostate androgen induced RNA (TMEPA) 1.5 3.08 F5'ttcattccctgtcctcattgg3'
R5'gcacaacagccatggaatca3'
Insulin like growth factor binding protein 7 (IGFBP7) 1.49 2.72 5' ggtccttccatagtgacgcc 3'
5' tctgaatggccaggttgtcc 3'
Matrix metalloprotease 2 (MMP2) 1.0 1.32 5' ctgatggcacccatttacacc 3'
5' gcctcgtataccgcatcaatc 3'
Transglutaminase 2 (TGM2) 1.2 3.27 5' ccatgaccagaacagcaacct3'
5' tgacctccgcaaagacaaag 3'
Thrombospondin 1 (TSP-1) 1.1 2.24 5' ccggcgtgaagtgtactagcta3'
5' tgcacttggcgttcttgtt 3'
Integrin αV 1.1 2.73 5' caggcttgcaacccattct 3'
5' cctggcgagtttggttttct 3'
RPL35a 5' gggtacagcatcactcgga 3'
5' acgcccgagatgaaacag 3'
The genes were selected based on any or both of the following criteria. 1. Genes that showed differential regulation between cell-lines and show 
maximum regulation in at least one of the cell-lines, 2. Genes that showed regulation in the array and are known as TGF-β regulated genes in other 
studies. The primer sequences are shown 5' to 3' and F and R denote forward and reverse primers respectively.BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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by treating the cells with 500 μg/ml of GRGDNP peptide,
a known Integrin pathway inhibitor, prior to treatment
with TGF-β. It was found that the induction of TSP-1,
which is a TGF-β regulated gene only in A549 cells, is
affected by blocking the integrin-linked signalling path-
way (Figure 7 and Figure 8). Blocking this pathway had no
effect on the regulation of the other genes tested. This sug-
gests that the Integrin pathway is also responsible for dif-
ferential regulation of some genes by TGF-β in the two
cell-types, HPL1D and A549.
Discussion
Most actions of TGF-β are brought about by regulation of
gene expression. The genes, which are regulated and the
way they are regulated are largely dependent on the cell-
type under consideration. Over the past few years, there
have been several independent transcriptome analyses of
cells in response to TGF-β treatment. In cells of epithelial
origin like human keratinocytes and mouse breast epithe-
lial cells, TGF-β modulates genes involved in EMT [23,24].
In lung fibroblasts and A549 cells, TGF-β treatment results
in the induction of extracellular matrix genes which are
responsible for fibrosis as in the case of idiopathic pulmo-
nary and alveolar epithelial fibrosis [25,26]. Studies using
various cells such as cervical cancer cells, corneal epithe-
lial cells, rat intestinal epithelial cells, and dermal fibrob-
lasts show that regulation of gene expression by TGF-β is
cell-type specific [27-30]. Considering the dual role of
TGF-β on normal and transformed cells, wherein it con-
fers growth inhibition and apoptosis to normal epithelial
cells but aids growth and metastasis of tumour cells [4-7],
it is essential to identify the genes and/or biochemical
pathways regulated by TGF-β in normal and transformed
cells. An understanding of these differences may allow
identification of therapeutic targets for diseases involving
TGF-β signalling pathway.
With this aim, expression profiling of genes in response to
TGF-β was performed in a lung adenocarcinoma cell-line
(A549) and a matched immortalized lung epithelial cell-
line (HPL1D). The experimental design includes treat-
ment of the respective cells with 5 ng/ml TGF-β in serum
free conditions for 1, 4 and 12 hrs and extract RNA for
microarray experiments. In our experiments, we have used
two arrays for each RNA (time point) and hence essen-
tially these are technical duplicates. As a consequence
although duplicate arrays were performed for each time
point, effectively the sample size equals to 1 at each time
point since they are technical duplicates. Due to this, it is
possible that many changes that are seen could be due to
variations in the experimental protocols, rather than real
biological differences. To overcome this, we have per-
qRT-PCR analyses of selected genes (TMEPA, TGFBIP, IGFBP7, Integrin αV, TSP-1, MMP2, TGM2) with respect to TGF-β  treatment in HPL1D cells Figure 4
qRT-PCR analyses of selected genes (TMEPA, TGFBIP, IGFBP7, Integrin αV, TSP-1, MMP2, TGM2) with 
respect to TGF-β treatment in HPL1D cells. The cells were grown to 90% confluence, washed with serum free medium 
and treated with 5ng/ml TGF-β 1 for 1, 4, 6, 12 and 24 hours along with untreated controls at each time-point. Two microgram 
of total RNA from each treatment was reverse transcribed and cDNA equivalent to 10ng total RNA was used for the PCR 
reactions. The graphs represent the fold change over untreated controls after normalization with the expression of RPL35a. 
The bars show mean ± SD of two experiments of the PCR reactions done in duplicates.
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formed qRT-PCR validation of several genes on biological
replicates that agrees with the microarray data for the
respective genes. Our data showed similar regulation of
267 genes in HPL1D and A549 cells by TGF-β. This sug-
gests that the genes commonly regulated in both HPL1D
and A549 are not tumour specific. Some of these genes
were also reported to be regulated by TGF-β in other stud-
ies using microarray in various cell-types [23,24,27] sug-
gesting that these TGF-β regulated genes are not tumour
cell specific but generally regulated by TGF-β. While some
1757 genes are exclusively regulated by TGF-β in A549,
only 733 genes are exclusively regulated in HPL1D cells.
The reasons for this differential response are not known.
However, some of the genes exclusively regulated in A549
such as Integrin αV, thrombospondin 1,
α2macroglobulin have been shown to aid tumour sur-
vival, maintenance and metastasis [31-33]. In contrast, in
HPL1D, TGF-β regulates tumour suppressor genes like
Table 3: TGF-β regulated genes (19) in HPL1D involved in focal adhesion
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
AA031376 PLACENTAL GROWTH FACTOR, VASCULAR ENDOTHELIAL GROWTH FACTOR-RELATED PROTEIN 1.18 ± 0.47 1.36 ± 0.05 1.16 ± 0.04
AA046597 INTEGRIN, BETA 4 1.63 ± 0.14 1.57 ± 0 1.43 ± 0.07
AA131272 INTEGRIN, ALPHA 8 1.19 ± 0 1.38 ± 0.06 0.96 ± 0.02
AW959692 VASCULAR ENDOTHELIAL GROWTH FACTOR C 1.15 ± 0.17 1.34 ± 0.02 1.44 ± 0.31
N74737 COLLAGEN, TYPE IV, ALPHA 2 0.84 ± 0.01 1 ± 0.04 1.51 ± 0.01
AA030029 PROTEIN KINASE C, ALPHA 1.3 ± 0 1.14 ± 0.03 1.1 ± 0.07
AL079948 THROMBOSPONDIN 1 0.78 ± 1.82 ± 0.09 2.5 ± 0.1
H73128 INTEGRIN, BETA 5 1.06 ± 0.03 1.21 ± 0.03 1.47 ± 0.11
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) 1.11 ± 0.08 1.14 ± 0.03 1.55 ± 0.07
BM801832 CAVEOLIN 1, CAVEOLAE PROTEIN, 22 KDA 1.09 ± 0.11 1.4 ± 0.01 1.47 ± 0
W67710 PLATELET-DERIVED GROWTH FACTOR BETA POLYPEPTIDE (SIMIAN SARCOMA VIRAL (V-SIS) ONCOGENE 
HOMOLOG)
1.53 ± 0.07 1.17 ± 0.02 1.2 ± 0.01
W20454 FIBRONECTIN 1 1.23 ± 0 1.36 ± 0.04 2.1 ± 0.19
AA029359 LAMININ, BETA 2 (LAMININ S) 1.54 ± 0.06 1.17 ± 0.08 1.02 ± 0.06
W39107 RAS HOMOLOG GENE FAMILY, MEMBER A 1.37 ± 0.05 1.07 ± 0.04 1.14 ± 0.16
AA043301 COLLAGEN, TYPE IV, ALPHA 1 1.4 ± 0.19 1.52 ± 1.52 ± 0.03
BQ017489 ACTININ, ALPHA 1 1.42 ± 0.03 1.02 ± 0.11 1.53 ± 0.2
AA010526 GLUCOCORTICOID RECEPTOR DNA BINDING FACTOR 1 1.37 ± 0.26 1.29 ± 0.07 1.36 ± 0.02
R14058 PROTEIN KINASE C, BETA 1 1.34 ± 0.02 0.81 ± 0.1 0.94 ± 0.03
H58824 DIAPHANOUS HOMOLOG 1 (DROSOPHILA) 0.84 ± 0.1 1.57 ± 0.19 1 ± 0.11
For description see legend of table 2
Table 2: TGF-β regulated genes (17) in HPL1D involved in regulation of actin cytoskeleton
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
W20454 FIBRONECTIN 1 1.23 ± 0 1.36 ± 0.04 2.1 ± 0.19
H58824 DIAPHANOUS HOMOLOG 1 (DROSOPHILA) 0.84 ± 0.1 1.57 ± 0.19 1 ± 0.11
N46724 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 7 1.4 ± 0.07 0.96 ± 0.21 1 ± 0.07
AA045207 ACTIN RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 5, 16KDA 1.3 ± 0.09 1.3 ± 0.23 1.55 ± 0.12
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP 
BINDING PROTEIN RAC1)
1.11 ± 0.08 1.14 ± 0.03 1.55 ± 0.07
BQ017489 ACTININ, ALPHA 1 1.42 ± 0.03 1.02 ± 0.11 1.53 ± 0.2
H73128 INTEGRIN, BETA 5 1.06 ± 0.03 1.21 ± 0.03 1.47 ± 0.11
W56632 CD14 ANTIGEN 1.46 ± 0 1.15 ± 0 1.45 ± 0.06
AA046597 INTEGRIN, BETA 4 1.63 ± 0.14 1.57 ± 0 1.43 ± 0.07
H23109 FIBROBLAST GROWTH FACTOR 1 (ACIDIC) 1.55 ± 0.1 0.94 ± 0.08 1.42 ± 0.2
AA010526 GLUCOCORTICOID RECEPTOR DNA BINDING FACTOR 1 1.37 ± 0.26 1.29 ± 0.07 1.36 ± 0.02
W67710 PLATELET-DERIVED GROWTH FACTOR BETA POLYPEPTIDE (SIMIAN SARCOMA 
VIRAL (V-SIS) ONCOGENE HOMOLOG)
1.53 ± 0.07 1.17 ± 0.02 1.2 ± 0.01
AA037763 WAS PROTEIN FAMILY, MEMBER 2 1.41 ± 0.08 1.08 ± 0.02 1.18 ± 0.05
W39107 RAS HOMOLOG GENE FAMILY, MEMBER A 1.37 ± 0.05 1.07 ± 0.04 1.14 ± 0.16
AL598940 MYOSIN, LIGHT POLYPEPTIDE 1, ALKALI; SKELETAL, FAST 1.36 ± 0.05 1.06 ± 0.12 1.07 ± 0.02
AA131272 INTEGRIN, ALPHA 8 1.19 ± 0 1.38 ± 0.06 0.96 ± 0.02
H83405 FYVE, RHOGEF AND PH DOMAIN CONTAINING 1 (FACIOGENITAL DYSPLASIA) 0.45 ± 0.01 0.52 ± 0.17 0.25 ± 0
The list in the table shows the regulated genes as revealed by the DAVID tool. The columns show Genbank accession no., gene name, and fold 
change with respect to untreated controls at 1 hr, 4 hr and 12 hr time points following TGF-β treatment respectively. The regulation shown against 
each gene is depicted as fold change ± S.E. with respect to untreated cells. Each experimental value of the duplicates of the respective genes is 
shown in tables S1 and S3 (see additional file 1 and 3). The number in the parenthesis of the title represents the number of genes in the table.BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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Table 4: TGF-β regulated genes (15) in HPL1D involved in wnt signaling
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
N92026 PROTEIN PHOSPHATASE 3 (FORMERLY 2B), CATALYTIC SUBUNIT, BETA ISOFORM (CALCINEURIN A BETA) 0.92 ± 0.06 1.31 ± 0.01 1.05 ± 0.11
H82025 PRICKLE-LIKE 1 (DROSOPHILA) 1.79 ± 0.18 1.17 ± 0.02 1.21 ±
AA044665 F-BOX AND WD-40 DOMAIN PROTEIN 11 1.24 ± 0.18 1.14 ± 1.42 ± 0.08
AA030029 PROTEIN KINASE C, ALPHA 1.3 ± 0 1.14 ± 0.03 1.1 ± 0.07
AA203216 PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY SUBUNIT B (PR 52), BETA ISOFORM 1.26 ± 0 1.07 ± 0.2 1.5 ± 0.04
H79065 PRICKLE-LIKE 2 (DROSOPHILA) 1.38 ± 0.07 1.04 ± 0.28 1.01 ± 0.14
BM921730 PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY SUBUNIT A (PR 65), BETA ISOFORM 1.48 ± 0.01 1.19 ± 0.06 1.17 ± 0.01
R23027 CASEIN KINASE 1, ALPHA 1 1.28 ± 0.08 1.46 ± 0.01 1.26 ± 0.08
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) 1.11 ± 0.08 1.14 ± 0.03 1.55 ± 0.07
BM311217 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 4 1.26 ± 0.09 1 ± 0.06 1.34 ± 0.02
W86518 C-TERMINAL BINDING PROTEIN 2 1.33 ± 0.01 1.35 ± 0.24 1.13 ± 0.07
H70045 CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE (CAM KINASE) II GAMMA 1.48 ± 0.16 1.1 ± 0.01 1.16 ± 0.05
W39107 RAS HOMOLOG GENE FAMILY, MEMBER A 1.37 ± 0.05 1.07 ± 0.04 1.14 ± 0.16
BE618078 CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE (CAM KINASE) II BETA 1.58 ± 0.02 0.86 ± 0.05 1.02 ± 0.1
R14058 PROTEIN KINASE C, BETA 1 1.34 ± 0.02 0.81 ± 0.1 0.94 ± 0.03
For description see legend of table 2
Table 5: TGF-β regulated genes (38) in A549 involved in MAP kinase signalling
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
H09832 ACTIVIN A RECEPTOR, TYPE IB 1.01 ± 0.17 1.66 ± 0.29 1.17 ± 0.06
N27681 HEAT SHOCK 70 KDA PROTEIN 1A 1.12 ± 0.01 1.46 ± 0.18 1.42 ± 0.08
H73255 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 6 0.84 ± 0.31 1.04 ± 0.07 1.49 ± 0.11
N42722 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), GAMMA 12 1.44 ± 0.04 1.5 ± 0.09 1.28 ± 0.17
AA039598 RIBOSOMAL PROTEIN S6 KINASE, 90 KDA, POLYPEPTIDE 1 1.16 ± 0.13 1.21 ± 0.02 1.32 ± 0.02
AA030029 PROTEIN KINASE C, ALPHA 1.33 ± 0.23 1.56 ± 0.08 1.36 ± 0.03
H73472 CELL DIVISION CYCLE 42 (GTP BINDING PROTEIN, 25 KDA) 1.24 ± 0.27 1.33 ± 0.07 1.56 ± 0.01
H62639 HEAT SHOCK 70 KDA PROTEIN 8 1.29 ± 0.01 1.68 ± 0.18 1.37 ± 0
H23019 TRANSFORMING GROWTH FACTOR, BETA RECEPTOR I (ACTIVIN A RECEPTOR TYPE II-LIKE KINASE, 53 
KDA)
1.09 ± 0.01 2.53 ± 0.07 2.11 ± 0.41
AA088648 FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME) 1.45 ± 0.24 1.97 ± 0.08 1.77 ± 0.09
AV747676 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PROTEIN KINASE B, GAMMA) 1.06 ± 0.13 1.46 ± 0.05 1.18 ± 0.01
AI500475 RAS GUANYL RELEASING PROTEIN 1 (CALCIUM AND DAG-REGULATED) 1.31 ± 0.05 1.37 ± 0 1.41 ± 0.07
R86053 NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B-CELLS 2 (P49/P100) 0.99 ± 0.12 0.9 ± 0.07 1.44 ± 0.09
BE502112 RIBOSOMAL PROTEIN S6 KINASE, 90 KDA, POLYPEPTIDE 3 0.37 ± 0.1 0.29 ± 0.05 0.41 ± 0.06
H23109 FIBROBLAST GROWTH FACTOR 1 (ACIDIC) 0.94 ± 1.36 ± 0.01 1.13 ± 0.05
AA127934 PROTEIN KINASE, X-LINKED 1.21 ± 0.07 1.38 ± 0.01 1.35 ± 0.07
H89206 PROTEIN KINASE, CAMP-DEPENDENT, CATALYTIC, BETA 1.18 ± 0.08 1.42 ± 0.04 1.25 ± 0.03
R14348 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 1.45 ± 0.09 1.22 ± 0.17 1.03 ± 0.06
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) 1.39 ± 0 1.41 ± 0.06 1.28 ± 0.18
H11708 MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4 1.38 ± 0.02 1.54 ± 0.1 1.24 ± 0.17
R36401 FILAMIN B, BETA (ACTIN BINDING PROTEIN 278) 0.96 ± 0.02 1.17 ± 0.11 1.33 ± 0.01
BI758537 MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE C (MYOCYTE ENHANCER FACTOR 2C) 1.77 ± 0.42 1.25 ± 1.36 ± 0.09
W56249 ACTIVATING TRANSCRIPTION FACTOR 2 1.25 ± 0.13 1.5 ± 0.02 1.72 ± 0.18
AA034981 INTERLEUKIN 1 RECEPTOR, TYPE I 0.37 ± 0.08 0.4 ± 0.02 0.29 ± 0.04
AA056664 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 1.34 ± 0.15 1.44 ± 0.05 1.36 ± 0.07
H20677 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7 INTERACTING PROTEIN 1 1.13 ± 0.15 0.96 ± 0.1 1.6 ± 0.01
BM999610 V-JUN SARCOMA VIRUS 17 ONCOGENE HOMOLOG (AVIAN) 1.57 ± 0.26 2.13 ± 0.01 1.66 ± 0.18
BE781203 CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA 1G SUBUNIT 1.13 ± 0.03 1.02 ± 0 1.44 ± 0
T83272 RAS P21 PROTEIN ACTIVATOR 2 0.96 ± 0.08 1.12 ± 0.18 1.33 ± 0.02
T75436 MITOGEN-ACTIVATED PROTEIN KINASE 10 1.16 ± 0.17 1.22 ± 0.05 1.37 ± 0.07
W70006 CELL DIVISION CYCLE 25B 1.47 ± 0.1 1.15 ± 0.05 1.38 ± 0.08
R32409 PHOSPHOLIPASE A2, GROUP V 1.14 ± 0.27 1.27 ± 0.01 1.5 ± 0.07
AW96187
3
CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA SUBUNIT 4 1.45 ± 0.15 1.23 ± 0.17 1.02 ± 0
BI752921 PLATELET-DERIVED GROWTH FACTOR RECEPTOR, BETA POLYPEPTIDE 1.43 ± 0.09 1.03 ± 0.02 1.09 ± 0.07
BQ055308 RIBOSOMAL PROTEIN L4 1.44 ± 0.05 1.26 ± 0.04 1.43 ± 0.08
R14058 PROTEIN KINASE C, BETA 1 1.54 ± 0.06 1.08 ± 0.01 1.15 ± 0
BQ016117 V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG 1.48 ± 0.26 1.44 ± 0.04 1.29 ± 0.06
W05234 CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA 3 SUBUNIT 1.4 ± 0.07 1.15 ± 0.05 1.27 ± 0
The list in the table shows the regulated genes as revealed by the DAVID tool. The columns show Genbank accession no., gene name, and fold change with respect to 
untreated controls at 1 hr, 4 hr and 12 hr time points following TGF-β treatment respectively. The regulation shown against each gene is depicted as fold change ± S.E. with 
respect to untreated cells. Each experimental value of the duplicates of respective genes is shown in tables S1 and S2 (see additional files 1 and 2). The number in the 
parenthesis of the title represents the number of genes in the table.BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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WT1, ECM proteins like collagen which are responsible
for arrest of cell growth and apoptosis. This differential
gene regulation in normal and tumour cells may explain
the dual role of TGF-β in carcinogenesis. When the genes
regulated by TGF-β in these two cell-lines were categorized
based on their annotated functions, it was found that sig-
nalling pathways like MAP kinase, focal adhesion, Wnt
signalling are regulated by TGF-β in both the cell-lines.
On the other hand, Integrin αV was found to be differen-
tially regulated in A549 and HPL1D cells.
TGF-β actions on cells are to a large extent are carried out
by the phosphorylation of SMAD 2/3 by activated TGF-β
type I receptor upon TGF-β signalling. Several genes that
are transcriptionally regulated by TGF-β contain a SMAD
complex binding element (SBE). However, many genes
are reported to be regulated by TGF-β through an AP1 ele-
ment [34,35]. Using SMAD2/SMAD3 knock out fibroblast
cell-lines, SMAD 2 and 3 independent actions of TGF-β
have been reported earlier [36]. In addition, SMAD inde-
pendent signalling by TGF-β mediated by other pathways
like the MAP kinases namely the p38, ERK and the JNK
pathways is also reported [18-20,37-40]. Activation of the
p38 and the JNK pathways by TGF-β involves a TGF-β acti-
vated kinase called TAK1 (reviewed in [41,42]). However,
the ERK pathway activation by TGF-β is not well character-
ized. Also, cross talk between SMAD mediated signalling
and PKC pathway has been reported [43]. Another path-
way that has been implicated in TGF-β actions is the
integrin signalling pathway. It has been shown that activa-
tion of integrin β 1 along with αV is important for the
EMT mediated by TGF-β [22]. Although, Integrin αV is
known to mediate some actions of TGF-β in some cell-
types [21,22,44-46], the genes regulated by TGF-β
through this pathway have not been characterized. Our
data suggest substantial induction of integrin αV by TGF-
β in only A549 cells and marginally in HPL1D cells. This
could be an important difference between these two cell-
lines for the regulation of gene expression mediated by
TGF-β via this pathway. In order to understand the mech-
anism of regulation of some of the previously validated
genes identified in the microarray experiments, specific
inhibitors for the three branches of the MAP kinase path-
way namely the p38, the ERK and the JNK pathways were
used prior to TGF-β treatment of the cells and expression
of these genes was studied by real time qRT-PCR estima-
tion. The results suggested that in A549 cells, active MAP
kinase pathways are involved in the regulation of more
number of genes with relatively higher magnitude by TGF-
β as compared to HPL1D cells (Fig. 5&6). There could be
several reasons for this observation: 1] It is known that the
MAP kinases are constitutively active in highly malignant
cells due to autocrine activation of MAP kinase pathways
[47], PI3K/Akt pathways [48], constitutive activation or
amplification of receptors such as EGFR, PDGFR etc.,
mechanisms [49]. MAP kinase pathway involvement in
the TGF-β mediated gene regulation is well established
and the constitutive activation of MAP kinase pathway in
transformed cells could be one of the reasons for more
number of genes regulated by TGF-β in A549 cells. 2] It
could be due to activation of Integrin pathway in trans-
formed cells. It has been reported that Integrin mediated
FAK/ILK activation is required for the regulation of EMT
[22,50]. Our data suggesting regulation of Thrombospon-
din 1 which is an EMT marker [51] by TGF-β via integrin
pathway, could be an example of this pathway's impor-
Table 6: TGF-β regulated genes (21) in A549 involved in tight junction
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
AA027986 PROTEIN PHOSPHATASE 2 (FORMERLY 2A), CATALYTIC SUBUNIT, ALPHA ISOFORM 1.24 ± 0.15 1.65 ± 0.03 1.34 ± 0.11
H80401 V-YES-1 YAMAGUCHI SARCOMA VIRAL ONCOGENE HOMOLOG 1 0.3 ± 0.19 0.2 ± 0.07 0.29 ± 0.01
R52046 ACTININ, ALPHA 4 1.26 ± 0.68 1.21 ± 1.81 ± 0.21
AA030029 PROTEIN KINASE C, ALPHA 1.33 ± 0.23 1.56 ± 0.08 1.36 ± 0.03
BE738680 RAS HOMOLOG GENE FAMILY, MEMBER A 1.24 ± 0.11 1.4 ± 0.06 1.51 ± 0.03
H73472 CELL DIVISION CYCLE 42 (GTP BINDING PROTEIN, 25 KDA) 1.24 ± 0.27 1.33 ± 0.07 1.56 ± 0.01
N92643 CALCIUM/CALMODULIN-DEPENDENT SERINE PROTEIN KINASE (MAGUK FAMILY) 1.31 ± 1.45 ± 0.01 1.03 ± 0.01
BI828016 SPECTRIN, ALPHA, NON-ERYTHROCYTIC 1 (ALPHA-FODRIN) 1.33 ± 0.08 1.38 ± 0.01 1.93 ± 0.04
AV747676 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PROTEIN KINASE B, GAMMA) 1.06 ± 0.13 1.46 ± 0.05 1.18 ± 0.01
AA031382 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), ALPHA INHIBITING ACTIVITY POLYPEPTIDE 2 1.23 ± 0.04 1.21 ± 0.05 1.65 ± 0.21
R14061 PAR-3 PARTITIONING DEFECTIVE 3 HOMOLOG (C. ELEGANS) 1.52 ± 0.07 1.12 ± 0.04 1.05 ± 0
AA056664 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 1.34 ± 0.15 1.44 ± 0.05 1.36 ± 0.07
BI553762 CATENIN (CADHERIN-ASSOCIATED PROTEIN), ALPHA 2 1.36 ± 0.06 1.17 ± 0.03 1.88 ± 0.21
BM993684 CORTACTIN 1.63 ± 0.07 1.32 ± 0.11 1.26 ± 0.08
AA009869 ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1 (ELLIPTOCYTOSIS 1, RH-LINKED) 1.19 ± 0.13 1.21 ± 0.05 1.39 ± 0.02
AA058385 TIGHT JUNCTION PROTEIN 2 (ZONA OCCLUDENS 2) 1.35 ± 0.15 1.36 ± 0.02 1.16 ± 0.18
AI375078 KIAA1634 PROTEIN 1.48 ± 0.02 1.25 ± 0.03 1.04 ± 0.01
BM978991 MEMBRANE ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAIN CONTAINING 2 1.1 ± 0.05 1.15 ± 0 1.47 ± 0.05
N43838 ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1-LIKE 3 1.4 ± 0.08 1.15 ± 0.14 1.15 ± 0.09
BQ017489 ACTININ, ALPHA 1 1.57 ± 0.22 1.24 ± 0.1 1.5 ± 0.1
R14058 PROTEIN KINASE C, BETA 1 1.54 ± 0.06 1.08 ± 0.01 1.15 ± 0
For description see legend of table 5BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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tance in TGF-β mediated gene regulation at least with
respect to genes that mediate EMT. Taken together, our
data highlights the importance of MAP kinase and
integrin pathways in the regulation of majority of genes
by TGF-β at least in transformed cells. The role of SMAD
pathway in the regulation of these genes that are affected
by the MAP kinase and integrin αV inhibitors is not
known. It is possible that some of these regulations that
depend on non-SMAD pathways may also need activated
SMAD pathway. One difference between normal and
tumour cells could be the absence of an intact SMAD sig-
nalling pathway in tumour cells. However, in A549 cells,
no defects in the SMAD pathway have been reported. In
addition, we confirmed the presence of intact SMAD path-
way in A549 cells by SMAD dependent regulation of pro-
moter activity by TGF-β (See additional file 5, Fig. S2).
Based on our data, we propose that activated MAP kinase
pathway could be one of the essential determining factors
for the various differential actions of TGF-β in tumour
cells.
A major question that remains to be addressed is whether
the TGF-β mediated differential gene expression patterns
in HPL1D and A549 cells is due to the distinct phenotypic
characteristics of the respective cell-lines. From the previ-
ous studies, it is well established that TGF-β influences the
growth and apoptosis of untransformed epithelial cells
such as lung epithelial cells [52]. At least the growth inhi-
bition by TGF-β has been less sensitive in the presence of
serum [53] suggesting that activation of signalling path-
ways by serum may antagonize TGF-β mediated growth
inhibition. Most apoptosis studies using TGF-β have also
been carried out in minimal serum conditions (0.2–0.5
%). It remains to be established if apoptotic cell death
Effect of inhibition of the MAP kinase pathways on the regulation of gene expression by TGF-β in A549 cells Figure 5
Effect of inhibition of the MAP kinase pathways on the regulation of gene expression by TGF-β in A549 cells. 
The cells were grown to 90% confluence, washed with serum free medium, treated with 10 μM p38 inhibitor (SB203580), ERK 
inhibitor (PD98059) or JNK inhibitor 1 hour prior to treatment with TGF-β. The cells were harvested after 18 hours following 
TGF-β treatment and processed for qRT-PCR as described in Figure 3.
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Table 7: TGF-β regulated genes (21) in A549 involved in adherans junction
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
H78804 SMAD, MOTHERS AGAINST DPP HOMOLOG 3 (DROSOPHILA) 1.22 ± 0.09 1.36 ± 0.02 1.15 ± 0.06
H09832 ACTIVIN A RECEPTOR, TYPE IB 1.01 ± 0.17 1.66 ± 0.29 1.17 ± 0.06
H80401 V-YES-1 YAMAGUCHI SARCOMA VIRAL ONCOGENE HOMOLOG 1 0.3 ± 0.19 0.2 ± 0.07 0.29 ± 0.01
R52046 ACTININ, ALPHA 4 1.26 ± 0.68 1.21 ± 1.81 ± 0.21
AA029516 TRANSCRIPTION FACTOR 7-LIKE 2 (T-CELL SPECIFIC, HMG-BOX) 1.25 ± 0.02 1.41 ± 0.02 1.14 ± 0.2
BE738680 RAS HOMOLOG GENE FAMILY, MEMBER A 1.24 ± 0.11 1.4 ± 0.06 1.51 ± 0.03
H73472 CELL DIVISION CYCLE 42 (GTP BINDING PROTEIN, 25 KDA) 1.24 ± 0.27 1.33 ± 0.07 1.56 ± 0.01
H23019 TRANSFORMING GROWTH FACTOR, BETA RECEPTOR I (ACTIVIN A RECEPTOR TYPE II-LIKE 
KINASE, 53 KDA)
1.09 ± 0.01 2.53 ± 0.07 2.11 ± 0.41
AA088648 FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER 
SYNDROME)
1.45 ± 0.24 1.97 ± 0.08 1.77 ± 0.09
R55134 TRANSCRIPTION FACTOR 7-LIKE 1 (T-CELL SPECIFIC, HMG-BOX) 1.45 ± 0.03 1.2 ± 0.1 1.27 ± 0.05
BM314539 CATENIN (CADHERIN-ASSOCIATED PROTEIN), DELTA 1 1.35 ± 0.04 1.21 ± 0.08 1.05 ± 0.06
R14061 PAR-3 PARTITIONING DEFECTIVE 3 HOMOLOG (C. ELEGANS) 1.52 ± 0.07 1.12 ± 0.04 1.05 ± 0
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN 
RAC1)
1.39 ± 0 1.41 ± 0.06 1.28 ± 0.18
W24540 FERM, RHOGEF AND PLECKSTRIN DOMAIN PROTEIN 2 1.28 ± 0.06 1.37 ± 0.1 1.46 ± 0.05
BI553762 CATENIN (CADHERIN-ASSOCIATED PROTEIN), ALPHA 2 1.36 ± 0.06 1.17 ± 0.03 1.88 ± 0.21
R35167 BAI1-ASSOCIATED PROTEIN 2 1.46 ± 0.15 0.97 ± 0.02 1.32 ± 0.12
T82805 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, J 1.49 ± 0.09 1.35 ± 0.13 1.19 ± 0.08
AA069424 INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR 1.5 ± 0.09 1.16 ± 0.07 1.02 ± 0.05
N77112 IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN 1 1.6 ± 0.35 1.54 ± 0.13 1.48 ± 0.04
BQ017489 ACTININ, ALPHA 1 1.57 ± 0.22 1.24 ± 0.1 1.5 ± 0.1
AA005247 MET PROTO-ONCOGENE (HEPATOCYTE GROWTH FACTOR RECEPTOR) 1.68 ± 0.34 1.3 ± 0.03 1.14 ± 0.07
For description see legend of table 5
Effect of inhibition of the MAP kinase pathways on the regulation of gene expression by TGF-β in HPL1D cells Figure 6
Effect of inhibition of the MAP kinase pathways on the regulation of gene expression by TGF-β in HPL1D cells. 
The cells were grown to 90% confluence, washed with serum free medium, treated with 10 μM p38 inhibitor (SB203580), ERK 
inhibitor (PD98059) or JNK inhibitor 1 hour prior to treatment with TGF-β. The cells were harvested after 18 hours following 
TGF-β treatment and processed for qRT-PCR as described in Figure 3.
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mediated by TGF-β could be reversed in the presence of
serum although it can be speculated that reversal of
growth inhibition may allow survival of cells. One of the
most important actions of the serum is activation of
mitogenic pathways mediated by growth factors. Also, it
has been shown that serum stimulation leads to activation
of MAP kinase pathways [54]. Our data demonstrates that
the effect of TGF-β is more pronounced in A549 cells as
compared to HPL1D cells and one of the reasons for this
could be due to constitutively active MAP kinase pathway
in tumour cells. This is evident from our data that shows
loss of TGF-β regulation of many genes following MAP
kinase pathway specific inhibitors in A549 cells. A549
cells harbour a mutation at the 12th codon of K-ras proto-
oncogene [55]. This mutation renders constitutive activa-
tion of RAS protein resulting in active MAP kinase path-
way in these cells. In HPL1D cells, there is no report of any
mutation in the RAS genes or constitutively active MAP
kinase pathway. It is possible that this may be one of the
major differences responsible for the differential regula-
tion of genes by TGF-β in these cell-lines. HPL1D cells are
growth inhibited by TGF-β [15]. The differential regula-
tion of certain tumour suppressor genes (WT1, S100A2,
TSSC1), cell cycle related genes (CDC34, CHEK1) and
extracellular matrix genes (fibronectin, collagen IV and
VIII) by TGF-β in HPL1D cells (see additional file 3, Table
S3) points to a growth regulatory activity of TGF-β in these
cells. On the other hand, as discussed previously, genes
that are known to play pro-tumourigenic roles such as
thrombospondin, integrins, transglutaminase, α2-mac-
roglobulin etc. are regulated in A549 cells (see additional
file 2, Table S2). Taken together, the differential regula-
tion of genes in A549 and HPL1D cells could be due to
pro-tumourigenic or growth inhibitory roles of TGF-β on
these cells.
Conclusion
In conclusion, by microarray and real time RT-PCR exper-
iments, we show that 1] TGF-β regulates more number of
genes in transformed cells as compared to non-trans-
Table 8: TGF-β regulated genes (36) in A549 involved in focal adhesion
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
N45505 VAV 1 ONCOGENE 0.64 ± 0.37 0.41 ± 0.11 0.31 ± 0.01
AA046597 INTEGRIN, BETA 4 1.26 ± 0.21 1.1 ± 0.19 1.8 ± 0.18
R52046 ACTININ, ALPHA 4 1.26 ± 0.68 1.21 ± 1.81 ± 0.21
AA030029 PROTEIN KINASE C, ALPHA 1.33 ± 0.23 1.56 ± 0.08 1.36 ± 0.03
BE738680 RAS HOMOLOG GENE FAMILY, MEMBER A 1.24 ± 0.11 1.4 ± 0.06 1.51 ± 0.03
H73472 CELL DIVISION CYCLE 42 (GTP BINDING PROTE IN, 25 KDA) 1.24 ± 0.27 1.33 ± 0.07 1.56 ± 0.01
W17002 INTEGRIN, ALPHA V (VITRONECTIN RECEPTOR, ALPHA POLYPEPTIDE, ANTIGEN CD51) 1.21 ± 0.06 2.32 ± 0.29 2.73 ± 0.28
AV747676 V-AKTMURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PROTEIN KINASE B, GAMMA) 1.06 ± 0.13 1.46 ± 0.05 1.18 ± 0.01
BM912016 P21(CDKN1A)-ACTIVATED KINASE 4 1.29 ± 0.03 1.1 ± 0.23 1.54 ± 0.03
BM008467 ZYXIN 0.95 ± 0.1 1.16 ± 0.14 1.41 ± 0.07
AA037738 HEPATOCYTE GROWTH FACTOR (HEPAPOIETIN A; SCATTER FACTOR) 1.43 ± 0.07 1.36 ± 0.03 1.06 ± 0.13
H89256 LAMININ, BETA 1 1.44 ± 0.02 1.4 ± 0.02 1.12 ± 0.07
AA026831 KINASE INSERT DOMAIN RECEPTOR (A TYPE III RECEPTOR TYROSINE KINASE) 1.17 ± 0.1 1.34 ± 0.02 1.06 ± 0.01
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) 1.39 ± 0 1.41 ± 0.06 1.28 ± 0.18
AA122291 COLLAGEN, TYPE V, ALPHA 2 1.1 ± 0.08 1.19 ± 0.13 1.43 ± 0.11
R36401 FILAMIN B, BETA (ACTIN BINDING PROTEIN 278) 0.96 ± 0.02 1.17 ± 0.11 1.33 ± 0.01
R20452 CALPAIN 10 1.19 ± 0.21 1.08 ± 0.06 1.5 ± 0.01
H15287 P21(CDKN1A)-ACTIVATED KINASE 6 1.47 ± 0.08 1.21 ± 0.05 1.57 ± 0.04
W24540 FERM, RHOGEF AND PLECKSTRIN DOMAIN PROTEIN 2 1.28 ± 0.06 1.37 ± 0.1 1.46 ± 0.05
T39460 PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, ALPHA ISOFORM 1.35 ± 0.17 1.38 ± 0.04 1.49 ± 0.15
AA056664 V-AKT MURINE THYMOMA VTRAL ONCOGENE HOMOLOG 1 1.34 ± 0.15 1.44 ± 0.05 1.36 ± 0.07
AA127854 INTEGRIN, ALPHA 5 (FIBRONECTIN RECEPTOR, ALPHA POLYPEPTIDE) 1.4 ± 0.08 1.12 ± 0.03 1.22 ± 0.06
BG497332 THROMBOSPONDIN 1 0.87 ± 0.01 1.1 ± 0.1 2.24 ± 0.11
R25275 GLYCOGEN SYNTHASE KINASE 3 BETA. 1.15 ± 0.16 1.36 ± 0.04 1.23 ± 0.06
BQ016959 COLLAGEN, TYPE IV, ALPHA 2 1.18 ± 0.07 1.3 ± 0 1.33 ± 0.09
BM999610 V-JUN SARCOMA VIRUS 17 ONCOGENE HOMOLOG (AVIAN) 1.57 ± 0.26 2.13 ± 0.01 1.66 ± 0.18
AA044582 INTEGRIN, BETA 8 0.33 ± 0.03 0.26 ± 0.04 0.25 ± 0
T75436 MITOGEN-ACTIVATED PROTEIN KINASE 10 1.16 ± 0.17 1.22 ± 0.05 1.37 ± 0.07
AA069424 INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR 1.5 ± 0.09 1.16 ± 0.07 1.02 ± 0.05
BI752921 PLATELET-DERIVED GROWTH FACTOR RECEPTOR, BETA POLYPEPTIDE 1.43 ± 0.09 1.03 ± 0.02 1.09 ± 0.07
N99223 INTEGRIN, ALPHA 9 1.46 ± 0.12 1.08 ± 1.29 ± 0.01
BQ017489 ACTININ, ALPHA 1 1.57 ± 0.22 1.24 ± 0.1 1.5 ± 0.1
AA010526 GLUCOCORTICOID RECEPTOR DNA BINDING FACTOR 1 1.44 ± 0.14 1.03 ± 0.04 1.31 ± 0
R14058 PROTEIN KINASE C, BETA 1 1.54 ± 0.06 1.08 ± 0.01 1.15 ± 0
AA005247 MET PROTO-ONCOGENE (HEPATOCYTE GROWTH FACTOR RECEPTOR) 1.68 ± 0.34 1.3 ± 0.03 1.14 ± 0.07
AA043909 PTK2 PROTEIN TYROSINE KINASE 2 0.52 ± 0.11 0.52 ± 0.12 0.34 ± 0
For description see legend of table 5BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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Table 9: TGF-β regulated genes (26) in A549 involved in insulin signalling
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
R23436 PROTEIN KINASE, CAMP-DEPENDENT, REGULATORY, TYPE II, ALPHA 0.32 ± 0.03 0.52 ± 0.03 0.22 ± 0.01
BI855956 LIPASE, HORMONE-SENSITIVE 1.17 ± 0.06 1.12 ± 0.1 1.38 ± 0.07
W32908 FORKHEAD BOX O1A (RHABDOMYOSARCOMA) 0.46 ± 0.17 0.38 ± 0.01 0.3 ± 0.05
R48236 SUPPRESSOR OF CYTOKINE SIGNALING 3 1.02 ± 0.21 1.51 ± 0 1.45 ± 0.09
BF034127 INSULIN RECEPTOR SUBSTRATE 2 0.3 ± 0.2 0.2 ± 0.09 0.33 ± 0.01
BG502582 CALMODULIN 1 (PHOSPHORYLASE KINASE, DELTA) 0.89 ± 0.02 1.41 ± 0.07 1.21 ± 0.14
R74161 PHOSPHORYLASE, GLYCOGEN; LIVER (HERS DISEASE, GLYCOGEN STORAGE DISEASE TYPE VI) 0.23 ± 0.06 0.28 ± 0.08 0.28 ± 0.02
AA030048 PROTEIN KINASE, CAMP-DEPENDENT, REGULATORY, TYPE I, BETA 1.1 ± 0.03 1.02 ± 0.06 1.31 ± 0.01
BM556894 RAPTOR 0.89 ± 1.34 ± 0.04 1.29 ± 0.19
AV747676 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PROTEIN KINASE B, GAMMA) 1.06 ± 0.13 1.46 ± 0.05 1.18 ± 0.01
AA127934 PROTEIN KINASE, X-LINKED 1.21 ± 0.07 1.38 ± 0.01 1.35 ± 0.07
H89206 PROTEIN KINASE, CAMP-DEPENDENT, CATALYTIC, BETA 1.18 ± 0.08 1.42 ± 0.04 1.25 ± 0.03
W35243 PHOSPHOFRUCTOKINASE, PLATELET 1.15 ± 0.05 1.39 ± 0.06 1.34 ± 0.17
T93745 EUKARYOTIC TRANSLATION INITIATION FACTOR 4E MEMBER 2 1.4 ± 0 1.09 ± 0.11 1.06 ± 0.03
T39460 PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, ALPHA ISOFORM 1.35 ± 0.17 1.38 ± 0.04 1.49 ± 0.15
H80740 PHOSPHOFRUCTOKINASE, MUSCLE 1.42 ± 0.05 1.25 ± 0.04 1.36 ± 0.14
AA056664 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 1.34 ± 0.15 1.44 ± 0.05 1.36 ± 0.07
H52478 TUBEROUS SCLEROSIS 2 1.23 ± 0.2 1.32 ± 0.05 1.4 ± 0.01
R25275 GLYCOGEN SYNTHASE KINASE 3 BETA 1.15 ± 0.16 1.36 ± 0.04 1.23 ± 0.06
H64260 PROTEIN KINASE, AMP-ACTIVATED, GAMMA 2 NON-CATALYTIC SUBUNIT 1.69 ± 1.21 ± 1.46 ± 0.05
T75436 MITOGEN-ACTIVATED PROTEIN KINASE 10 1.16 ± 0.17 1.22 ± 0.05 1.37 ± 0.07
T75267 FK506 BINDING PROTEIN 12-RAPAMYCIN ASSOCIATED PROTEIN 1 1.77 ± 0.24 1.37 ± 0.05 1.2 ± 0.06
H44888 SUPPRESSOR OF CYTOKINE SIGNALING 6 0.25 ± 0.13 0.16 ± 0.18 ± 0.01
H59587 ACETYL-COENZYME A CARBOXYLASE ALPHA 1.42 ± 0.44 1.32 ± 0.01 1.18 ± 0
H08429 TUBEROUS SCLEROSIS 1 1.43 ± 0.09 1.09 ± 0.07 1.35 ± 0.1
AA010882 GLYCOGEN SYNTHASE 1 (MUSCLE) 1.46 ± 0.07 1.15 ± 0 1.01 ± 0.08
For description see legend of table 5
Effect of blocking the Integrin-linked signalling on the regulation of gene expression by TGF-β in A549 cells Figure 7
Effect of blocking the Integrin-linked signalling on the regulation of gene expression by TGF-β in A549 cells. 
The cells were grown to 90% confluence, washed with serum free medium, treated with 500 μg/ml GRGDNP peptide 3 hours 
prior to treatment with TGF-β. The cells were harvested after 12 hours following TGF-β treatment and processed for qRT-
PCR as described in Figure 3.
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formed cells; 2] evidence for differential regulation of
gene expression in normal and tumour cells by TGF-β;
and 3] that involvement of MAP kinase pathways may be
one of the major mechanisms of TGF-β actions.
Methods
Cell-lines and cultures
A549, a lung adenocarcinoma cell-line was cultured in
DMEM (Sigma-Aldrich, USA) with 10% foetal bovine
serum (FBS), 100 units/ml penicillin and 100 μg/ml strep-
tomycin, 2.5 μg/ml fungizone (Invitrogen Life Sciences,
USA). HPL1D, an immortalized lung epithelial cell-line
was cultured in Ham's F-12 supplemented with 5% FBS, 5
μg/ml bovine insulin, 5 μg/ml human transferrin, 10-7M
hydrocortisone, 2 × 10-10M tri-iodo thyronine and 20 ng/
ml EGF [15]. All the cell-lines were maintained at 37°C in
a humid atmosphere with 5% CO2.
Treatments
The cell-lines were grown to 90% confluence in the
respective growth media followed by serum free washes (3
times) for 24 hours and then treated with 5 ng/ml TGF-β1
(R&D systems, USA) for different intervals of time. For sig-
nal transduction pathway inhibitor experiments, cells
were pre-treated with 10 μM SB203580 (p38 inhibitor),
10 μM PD98050 (ERK inhibitor), and 10 μM JNK inhibi-
tor I (L-form) (all from Calbiochem) for 1 hour, and 500
μg/ml GRGDNP peptide (custom synthesized) for 2–3
hours prior to TGF-β treatments.
RNA isolation, cDNA labelling and microarray analysis
Total RNA was isolated from cells using TRI reagent
(Sigma-Aldrich, USA) according to manufacturer's proto-
col. The RNA was re-precipitated with 0.3 M sodium ace-
tate (pH 5.2) and ethanol, further purified using RNAeasy
columns (Qiagen, GmbH, Germany). The RNA quantity
and quality were assessed by OD260 and OD280 measure-
ments on a spectrophotometer and the integrity was
determined by MOPS-formaldehyde gel. The labelling of
the cDNA for microarray was done using Micromax Direct
Labelling kit (Perkin Elmer Life Sciences Inc. USA) accord-
ing to manufacturer's instructions. For each labelling reac-
Table 10: TGF-β regulated genes (36) in A549 involved in regulation of actin cytoskeleton
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
H83405 FYVE, RHOGEF AND PH DOMAIN CONTAINING 1 (FACIOGENITAL DYSPLASIA) 0.57 ± 0.41 0.35 ± 0.26 ± 0.01
N45505 VAV 1 ONCOGENE 0.64 ± 0.37 0.41 ± 0.11 0.31 ± 0.01
N45518 NCK-ASSOCIATED PROTEIN 1 1.03 ± 0.12 1.76 ± 0.2 1.39 ± 0.18
AA046597 INTEGRIN, BETA 4 1.26 ± 0.21 1.1 ± 0.19 1.8 ± 0.18
R52046 ACTININ, ALPHA 4 1.26 ± 0.68 1.21 ± 1.81 ± 0.21
N42722 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), GAMMA 12 1.44 ± 0.04 1.5 ± 0.09 1.28 ± 0.17
AL598940 MYOSIN, LIGHT POLYPEPTIDE 1, ALKALI; SKELETAL, FAST 1.15 ± 0.01 1.33 ± 0.17 1.56 ± 0.02
BE738680 RAS HOMOLOG GENE FAMILY, MEMBER A 1.24 ± 0.11 1.4 ± 0.06 1.51 ± 0.03
H73472 CELL DIVISION CYCLE 42 (GTP BINDING PROTEIN, 25KDA) 1.24 ± 0.27 1.33 ± 0.07 1.56 ± 0.01
W17002 INTEGRIN, ALPHA V (VITRONECTIN RECEPTOR, ALPHA POLYPEPTIDE, ANTIGEN CD51) 1.21 ± 0.06 2.32 ± 0.29 2.73 ± 0.28
AA088648 FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME) 1.45 ± 0.24 1.97 ± 0.08 1.77 ± 0.09
N57424 T-CELL LYMPHOMA INVASION AND METASTASIS 1 1.35 ± 0.02 1.23 ± 0.04 1.34 ± 0.02
H10616 PROFILIN 2 1.44 ± 0.08 1.49 ± 0.11 1.1 ± 0
BM912016 P21(CDKN1A)-ACTIVATED KINASE 4 1.29 ± 0.03 1.1 ± 0.23 1.54 ± 0.03
H23109 FIBROBLAST GROWTH FACTOR 1 (ACIDIC) 0.94 ± 1.36 ± 0.01 1.13 ± 0.05
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) 1.39 ± 0 1.41 ± 0.06 1.28 ± 0.18
H15287 P21(CDKN1A)-ACTIVATED KINASE 6 1.47 ± 0.08 1.21 ± 0.05 1.57 ± 0.04
T39460 PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, ALPHA ISOFORM 1.35 ± 0.17 1.38 ± 0.04 1.49 ± 0.15
BM888157 THYMOSIN, BETA 4, X-LINKED 1.02 ± 1.58 ± 1.93 ± 0.14
T83174 ACTIN RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 1B, 41KDA 1.24 ± 0.08 1.06 ± 0.1 1.54 ± 0.04
AA127854 INTEGRIN, ALPHA 5 (FIBRONECTIN RECEPTOR, ALPHA POLYPEPTIDE) 1.4 ± 0.08 1.12 ± 0.03 1.22 ± 0.06
H27657 G PROTEIN-COUPLED RECEPTOR KINASE INTERACTOR 1 1.39 ± 0.09 1.11 ± 0.04 1.34 ± 0.25
N29131 MOESIN 1.37 ± 0.09 1.03 ± 0.06 1.42 ± 0.05
AA044582 INTEGRIN, BETA 8 0.33 ± 0.03 0.26 ± 0.04 0.25 ± 0
T77476 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), ALPHA 13 1.39 ± 0.41 1.59 ± 0.08 1.24 ± 0.14
R35167 BAI1-ASSOCIATED PROTEIN 2 1.46 ± 0.15 0.97 ± 0.02 1.32 ± 0.12
H06909 PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 12B 1.34 ± 0.03 1.16 ± 0.01 1.08 ± 0.03
H14999 RAC/CDC42 GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 6 0.22 ± 0.13 0.27 ± 0.14 0.28 ± 0
N77112 IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN 1 1.6 ± 0.35 1.54 ± 0.13 1.48 ± 0.04
BI752921 PLATELET-DERIVED GROWTH FACTOR RECEPTOR, BETA POLYPEPTIDE 1.43 ± 0.09 1.03 ± 0.02 1.09 ± 0.07
N99223 INTEGRIN, ALPHA 9 1.46 ± 0.12 1.08 ± 1.29 ± 0.01
BI258438 COFILIN 1 (NON-MUSCLE) 1.24 ± 0.09 1.08 ± 0.09 1.42 ± 0.04
BQ017489 ACTININ, ALPHA 1 1.57 ± 0.22 1.24 ± 0.1 1.5 ± 0.1
H51445 LIM DOMAIN KINASE 1 1.3 ± 0 1.02 ± 0.11 1.12 ± 0.01
AA010526 GLUCOCORTICOID RECEPTOR DNA BINDING FACTOR 1 1.44 ± 0.14 1.03 ± 0.04 1.31 ± 0
AA043909 PTK2 PROTEIN TYROSINE KINASE 2 0.52 ± 0.11 0.52 ± 0.12 0.34 ± 0
For description see legend of table 5BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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Effect of blocking the Integrin-linked signalling on the regulation of gene expression by TGF-β in HPL1D cells Figure 8
Effect of blocking the Integrin-linked signalling on the regulation of gene expression by TGF-β in HPL1D cells. 
The cells were grown to 90% confluence, washed with serum free medium, treated with 500 μg/ml GRGDNP peptide 3 hours 
prior to treatment with TGF-β. The cells were harvested after 12 hours following TGF-β treatment and processed for qRT-
PCR as described in Figure 3.
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Table 11: TGF-β regulated genes (23) in A549 involved in Wnt signalling
Acc No DAVID Gene Name 1 hr 4 hr 12 hr
H78804 SMAD, MOTHERS AGAINST DPP HOMOLOG 3 (DROSOPHILA) 1.22 ± 0.09 1.36 ± 0.02 1.15 ± 0.06
AA029506 CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE (CAM KINASE) II DELTA 1.29 ± 0.22 1.41 ± 0.07 1.44 ± 0.02
AA027986 PROTEIN PHOSPHATASE 2 (FORMERLY 2A), CATALYTIC SUBUNIT, ALPHA ISOFORM 1.24 ± 0.15 1.65 ± 0.03 1.34 ± 0.11
AA029516 TRANSCRIPTION FACTOR 7-LIKE 2 (T-CELL SPECIFIC, HMG-BOX) 1.25 ± 0.02 1.41 ± 0.02 1.14 ± 0.2
AA044665 F-BOX AND WD-40 DOMAIN PROTEIN 11 1.09 ± 0.02 1.31 ± 0.02 1.07 ± 0.1
AA030029 PROTEIN KINASE C, ALPHA 1.33 ± 0.23 1.56 ± 0.08 1.36 ± 0.03
BE738680 RAS HOMOLOG GENE FAMILY, MEMBER A 1.24 ± 0.11 1.4 ± 0.06 1.51 ± 0.03
R55134 TRANSCRIPTION FACTOR 7-LIKE 1 (T-CELL SPECIFIC, HMG-BOX) 1.45 ± 0.03 1.2 ± 0.1 1.27 ± 0.05
W49562 PHOSPHOLIPASE C, BETA 4 1.26 ± 0.25 1.27 ± 0.04 1.77 ± 0.27
AA127934 PROTEIN KINASE, X-LINKED 1.21 ± 0.07 1.38 ± 0.01 1.35 ± 0.07
H89206 PROTEIN KINASE, CAMP-DEPENDENT, CATALYTIC, BETA 1.18 ± 0.08 1.42 ± 0.04 1.25 ± 0.03
N72642 CALCYCLIN BINDING PROTEIN 1.38 ± 0.01 1.5 ± 0.12 1.08 ± 0.06
BM924824 RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) 1.39 ± 0 1.41 ± 0.06 1.28 ± 0.18
W51811 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5A 1.48 ± 0.1 1.54 ± 0.06 1.51 ± 0.19
BM311217 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 4 1.63 ± 0.97 ± 1.5 ± 0.02
R25275 GLYCOGEN SYNTHASE KINASE 3 BETA 1.15 ± 0.16 1.36 ± 0.04 1.23 ± 0.06
AA152025 FRIZZLED HOMOLOG 4 (DROSOPHILA) 1.47 ± 0.28 1.56 ± 0.14 1.27 ± 0.12
BM999610 V-JUN SARCOMA VIRUS 17 ONCOGENE HOMOLOG (AVIAN) 1.57 ± 0.26 2.13 ± 0.01 1.66 ± 0.18
T75436 MITOGEN-ACTIVATED PROTEIN KINASE 10 1.16 ± 0.17 1.22 ± 0.05 1.37 ± 0.07
AA028175 CULLIN 1 1.51 ± 0.15 1.15 ± 0.04 0.96 ± 0.02
H70045 CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE (CAM KINASE) II GAMMA 1.45 ± 0.08 1.39 ± 0.16 1.21 ± 0.12
R72188 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 5 1.27 ± 0.13 0.87 ± 1.38 ± 0.02
R14058 PROTEIN KINASE C, BETA 1 1.54 ± 0.06 1.08 ± 0.01 1.15 ± 0
For description see legend of table 5BMC Genomics 2007, 8:98 http://www.biomedcentral.com/1471-2164/8/98
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tion, 20 μg of total RNA was used. The control RNA was
labelled with Cy3-dUTP and the TGF-β 1 treated RNA
with Cy5-dUTP. Both the labelled products were mixed
and precipitated with 0.3 M sodium acetate (pH 5.2) and
ethanol. A small quantity of the precipitated labelled
cDNA was assessed for labelling efficiency on a 1% agar-
ose gel and scanned using the Typhoon 9210 scanner (GE
Life Sciences). 160 μl of hybridisation buffer (Ultrahyb,
Sigma-Aldrich, USA) was added to the probe, incubated at
75°C for 5 minutes and then added to the human 19 K
array (University Health network, Toronto). The hybridi-
sation was carried out in the GeneTAC Hyb Station
(Genomic Solutions, UK) at 65° for 4 hours, 60° for 4
hours and 55° for 10 hours. The slides were then washed
with medium stringency (2× SSC and 0.1% SDS), high
stringency (0.1× SSC and 0.1% SDS) and post wash (0.1×
SSC) buffers for 5 minutes each, dried and scanned using
a scanner (Scanarray Express, Perkin Elmer Life Sciences,
USA).
Microarray image and data analyses
All the image analyses have been done using the Quantar-
ray software (Perkin Elmer Life Sciences, USA). Filtering
and compilation of data have been done using Microsoft
Excel and Microsoft Access. Spots of compromised quality
and with low intensity were eliminated from the analysis.
The data was normalized by LOWESS method (Avadis
3.1, Strand Life Sciences, India), Cy5:Cy3 ratios were
established and log2 values were calculated. Hybridiza-
tions of RNA from each time point were performed on
duplicate (technical duplicate) arrays and only those
genes, which showed consistent regulation, have been
considered for analysis. Genes which show log2ratios
greater than 0.37 (1.3 fold induced) or less than -1.5 (3
fold down regulated) in the duplicate arrays at any one of
the time points have been considered as regulated by TGF-
β. The cut-off values for regulated genes were decided
based on our observation of the data where genes that
were known to be up regulated by TGF-β were showing >
1.3 and < 0.33 fold difference in the microarray.
Real Time PCR analyses
For cDNA synthesis, two micrograms of total RNA was
reverse transcribed using the ABI cDNA Archive kit
(Applied Biosystems, USA). Complementary DNA
(cDNA) equivalent to 10 ng of total RNA was used for all
the PCR reactions. The sequences of the primers are
shown in Table 1. All the PCR reactions have been done
using Dynamo SYBR green mix (Finnzymes, Finland) in
ABI Prism 7900HT sequence detection system (Applied
Biosystems, USA). The analysis has been done using SDS
2.1 software (Applied Biosystems, USA). For normaliza-
tion of RT-PCR data, RPL35a expression (which was pre-
viously found to be unchanged in microarray
experiments) was used and fold over control at each of the
time point has been calculated as follows
δCT = CTgene-CTRPL
δδCT = δCTtreated-δCTuntreated
Fold Change = 2-δδCT.
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Additional file 1
List of genes commonly regulated by TGF-β in HPL1D and A549 cell-
lines. A list of genes, which are regulated by TGF-β in both HPL1D and 
A549 cell-lines along with the fold changes at 1, 4 and 12 hrs of treat-
ment.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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Additional file 2
List of genes regulated by TGF-β in only A549 cell-line. A list of genes, 
which are regulated by TGF-β in A549 alone along with the fold changes 
at 1, 4 and 12 hrs of treatment.
Click here for file
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Additional file 3
List of genes regulated by TGF-β only in HPL1D cell-line. A list of genes, 
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fold changes at 1, 4 and 12 hrs of treatment.
Click here for file
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